A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Empagliflozin (Primary)
- Indications Cardiovascular disorders; Renal failure
- Focus Registrational; Therapeutic Use
- Acronyms EMPA-KIDNEY
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim GmbH International
- 01 Feb 2019 Status changed from not yet recruiting to recruiting.
- 13 Nov 2018 Planned initiation date changed from 15 Nov 2018 to 30 Nov 2018.
- 24 Jul 2018 Planned initiation date changed from 28 Sep 2018 to 15 Nov 2018.